LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment
AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle cell lymphoma and promising Phase III trial results for ENHERTU in breast cancer. These advances in oncology could add depth to the company's market performance. Meanwhile, broader market trends showed mixed movements, with the Dow Jones and S&P 500 rising, while Nasdaq slipped slightly. Despite a flat market overall last week due to investor anticipation of the Federal...